Optic Neuritis - Pipeline Review, H1 2018

  • ID: 4521320
  • Report
  • 52 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biogen Inc
  • Bionure Farma SL
  • Commence Bio Inc
  • Lipocure Ltd
  • Meta-IQ ApS
  • Teijin Pharma Ltd
  • MORE
Optic Neuritis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuritis - Pipeline Review, H1 2018, provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape.

Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon and flashing lights. Risk factors include age and genetic mutations.

Report Highlights:

This latest pipeline guide Optic Neuritis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 8 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biogen Inc
  • Bionure Farma SL
  • Commence Bio Inc
  • Lipocure Ltd
  • Meta-IQ ApS
  • Teijin Pharma Ltd
  • MORE
Introduction

Report Coverage

Optic Neuritis - Overview

Optic Neuritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuritis - Companies Involved in Therapeutics Development

Biogen Inc

Bionure Farma SL

Commence Bio Inc

Lipocure Ltd

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Teijin Pharma Ltd

Optic Neuritis - Drug Profiles

BN-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENX-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etomoxir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gypenoside - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylprednisolone sodium succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

opicinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Optic Neuritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Optic Neuritis - Dormant Projects

Optic Neuritis - Discontinued Products

Optic Neuritis - Product Development Milestones

Featured News & Press Releases

Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

Oct 01, 2015: Biogen Presents Phase 2 Data On Anti-LINGO-1 at ECTRIMS Congress

Apr 14, 2015: Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

Jan 08, 2015: Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Optic Neuritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Optic Neuritis - Pipeline by Biogen Inc, H1 2018

Optic Neuritis - Pipeline by Bionure Farma SL, H1 2018

Optic Neuritis - Pipeline by Commence Bio Inc, H1 2018

Optic Neuritis - Pipeline by Lipocure Ltd, H1 2018

Optic Neuritis - Pipeline by Meta-IQ ApS, H1 2018

Optic Neuritis - Pipeline by Mitochon Pharmaceuticals Inc, H1 2018

Optic Neuritis - Pipeline by Teijin Pharma Ltd, H1 2018

Optic Neuritis - Dormant Projects, H1 2018

Optic Neuritis - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Optic Neuritis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Biogen Inc
  • Bionure Farma SL
  • Commence Bio Inc
  • Lipocure Ltd
  • Meta-IQ ApS
  • Mitochon Pharmaceuticals Inc
  • Teijin Pharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll